Showing 1791-1800 of 2105 results for "".
- FDA Greenlights Phase 2a Trial of Intranasal Foralumab in Multiple System Atrophyhttps://practicalneurology.com/news/fda-greenlights-phase-2a-trial-of-intranasal-foralumab-in-multiple-system-atrophy/2476103/The Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application, permitting the evaluation of treatment with intranasal foralumab (Tiziana Life Sciences, New York, NY) for people with multiple system atrophy (MSA) in a phase 2a clinical trial (NCT06868628). MSA i
- Accelerated FDA Approval Granted to First Treatment Targeting H3 K27M-Mutant Diffuse Midline Gliomahttps://practicalneurology.com/news/fda-grants-accelerated-approval-to-first-treatment-targeting-h3-k27m-mutant-diffuse-midline-glioma/2476100/The Food and Drug Administration (FDA) granted accelerated approval to Modeyso (dordaviprone; Jazz Pharmaceuticals, Dublin, Ireland) for the treatment of adults and children aged ≥1 year with diffuse midline glioma harboring the H3 K27M mutation with disease progression following prior therapy. M
- New Findings Related to Blarcamesine Treatment for People with Alzheimer Disease Presented at AAIC 2025https://practicalneurology.com/news/new-findings-related-to-blarcamesine-treatment-for-people-with-alzheimer-disease-presented-at-aaic-2025/2475931/According to an analysis of results from the phase 2b/3 ANAVEX2-73-AD-004 clinical trial (NCT04314934), treatment with Anavex2-73 (blarcamesine; Anavex Life Sciences, New York, NY) yielded greater clinical response for people with Alzheimer disease (AD) who carried the homozygous wild-type (WT) <
- Study Compares Nurtec ODT vs 14 Other Treatments for Acute Migrainehttps://practicalneurology.com/news/study-compares-nurtec-odt-vs-14-other-treatments-for-acute-migraine/2475275/Nurtec ODT (rimegepant; Pfizer, New York, NY) treatment for acute migraine was found to have superior or comparable efficacy and a more favorable safety profile compared with 14 other commonly used medications, which included triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and compound a
- Sunosi Significantly Reduced Excessive Daytime Sleepiness and Obstructive Sleep Apnea Symptoms in Real-World Studyhttps://practicalneurology.com/news/sunosi-significantly-reduced-excessive-daytime-sleepiness-and-obstructive-sleep-apnea-symptoms-in-real-world-study/2475070/The results of a real-world analysis presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS) show that Sunosi (solriamfetol; Axsome Therapeutics, New York, NY) significantly reduced symptoms of excessive daytime sleepiness (EDS) in individuals with obstructive s
- FDA Authorizes First Prescription Digital Therapeutic for Preventing Episodic Migrainehttps://practicalneurology.com/news/fda-authorizes-first-prescription-digital-therapeutic-for-preventing-episodic-migraine/2474512/The Food and Drug Administration (FDA) has granted marketing authorization to CT-132, a prescription digital therapeutic developed by Click Therapeutics (New York, NY), for the preventive treatment of episodic migraine in adults. CT-132 is the first FDA-authorized prescription digital therapeutic
- Neurostimulation Device for Drug-Resistant Focal Epilepsy Demonstrates Significant, Long-Term Reductions in Seizureshttps://practicalneurology.com/news/neurostimulation-device-for-drug-resistant-focal-epilepsy-demonstrates-significant-long-term-reductions-in-seizures/2474345/Three-year data from a post-approval study (PAS; NCT02403843) of the NeuroPace Responsive Neurostimulation (RNS) System (Mountain View, CA) demonstrated significant and sustained reductions in seizures in adults with drug-resistant focal epilepsy (DRE). The results of the PAS presented at the Ame
- FDA Clears Brain–Computer Interface Device for the Measurement and Stimulation of Cortical Brain Activityhttps://practicalneurology.com/news/fda-clears-braincomputer-interface-device-for-the-measurement-and-stimulation-of-cortical-brain-activity/2474229/The Food and Drug Administration (FDA) has granted 510(k) clearance to the Layer 7 Cortical Interface device (Precision Neuroscience, New York Ci
- Substantially Higher Mortality Risk Demonstrated for Children and Adolescents with Severe Epilepsy and Sleep Apneahttps://practicalneurology.com/news/substantially-higher-mortality-risk-demonstrated-for-children-and-adolescents-with-severe-epilepsy-and-sleep-apnea/2474009/Study results presented at the American Academy of Neurology (AAN) 2025 Annual Meeting demonstrate that central sleep apnea (CSA) and other sleep apnea, including obstructive sleep apnea (OSA), are associated with an increased risk of mortality in children and adolescents aged 1 to 17 years with
- Norepinephrine Reuptake Inhibitor Treatment Significantly Reduced Cataplexy Attacks in People with Narcolepsy Type 1https://practicalneurology.com/news/nri-therapy-significantly-reduced-cataplexy-attacks-in-people-with-narcolepsy-type-1/2473965/Treatment with AXS-12 (reboxetine; Axsome, New York, NY), a highly selective norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator, was associated with significant reductions in cataplexy attacks in people with narcolepsy type 1 (NT1), according to results from the phase 3 SYMPH